Kornimate/medical-research-clean huggingface dataset:
influence of physical exercise on endothelial function in pregnant women

Conditions: Pregnancy; Preeclampsia; Exercise

Summary: the purpose of this study is to determine the effect of regular aerobic exercise on endothelial function in pregnancy.

preeclampsia is a common maternal disease that complicates 5% to 10% of pregnancies and remains as the major cause of maternal and neonatal mortality, especially in developing countries. cost-effective interventions aimed to prevent the development of preeclampsia are urgently needed. ethiopathogenesis of preeclampsia involves multiple mechanisms as oxidative stress, endothelial dysfunction, infections, maternal constitutional factors, and others. regular aerobic exercise recovers endothelial function, decreases oxidative stress and improves maternal constitutional factors. the purpose of this controlled clinical trial is to determine the effect of regular aerobic exercise on endothelium-dependent brachial artery flow-mediated dilatation. furthermore, the effect of exercise on biomarkers on vascular function and perinatal outcomes will be evaluated.

Eligibility criteria:
inclusion criteria: * primiparous women who have not participated in a structured exercise program, including significant amounts of walking for the past four months are eligible for the trial. * live foetus at the routine ultrasound scan and a normal pregnancy. * gestational age 16 to 20 weeks * written informed consent will be obtained from each woman prior to the inclusion in the study. exclusion criteria: * history of high blood pressure * chronic medical illnesses (cancer, renal, endocrinologic, psychiatric, neurologic, infectious and cardiovascular diseases) * persistent bleeding after week 12 of gestation * poorly controlled thyroid disease * placenta praevia, incompetent cervix, polyhydramnios, oligohydramnios * history of miscarriage in the last twelve months * diseases that could interfere with participation (following recommendations from acsm 2000, acog 2003).

Keywords: pregnancy preeclampsia exercise
seroprevalence study of cov-2-sars (covid-19) infection in patients with chronic inflammatory rheumatic diseases

Conditions: COVID-19; SARS-CoV Infection; Rheumatoid Arthritis; Spondyloarthritis; Ankylosing Spondylitis; Psoriatic Arthritis

Summary: the prevalence of sars-cov-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. the proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with cov-2-sars infection. our objective is to describe the prevalence of seroconversion to cov-2-sars by consecutive screening in routine care of patients with chronic inflammatory rheumatism with serological testing

the prevalence of sars-cov-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. the proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with cov-2-sars infection. some treatments for chronic inflammatory rheumatisms such as tnf inibitors appear to have a protective effect against severe forms of covid-19, while corticosteroids or other immunosuppressants may be associated with a higher prevalence of severe forms of covid-19. our objective is to describe the prevalence of seroconversion to cov-2-sars by consecutive screening in routine care of out and inpatients with chronic inflammatory rheumatism (i.e. rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis) by serological testing and to compare prevalence according to type of chronic inflammatory rheumatism, dmard class and symptomatic treatment (corticosteroid therapy, nsaids).

Eligibility criteria:
inclusion criteria: - patient with chronic inflammatory rheumatic disease (i.e. rheumatoid arthritis, psoriatic rheumatism, axial spondyloarthritis), coming for consultation or hospitalization as part of the usual follow-up of his condition exclusion criteria: - adult patient under legal protection (guardianship, curatorship)

Keywords: covid-19 sars-cov-2 infection rheumatoid arthritis spondyloarthritis
scar appearance after postoperative hydrocolloid dressing versus standard petrolatum ointment

Conditions: Scar; Skin Scarring; Skin Cancer; Wound Heal; Wound of Skin; Surgical Wound; Patient Satisfaction; Patient Preference; Surgical Incision

Summary: patients will be randomized either to receive standard daily dressing or hydrocolloid dressing using a randomization generator. after closing the wound with the sutures,the scar will be covered by a hydrocolloid dressing, which will be left in place for 7 days(experimental) or the standard dressing (control) that will be covered with petrolatum jelly and bandaging during this time period, which has to be re-applied daily. patients and dermatologic surgeons will then complete surveys 7 days, 30 days, and 90 days after surgery to evaluate the cosmetic appearance of these scars.


Eligibility criteria:
inclusion criteria: 1. adult \> 18 years of age 2. linear scars 3. patients underwent conventional excision or mohs micrographic surgery for primary cutaneous cancer or other cutaneous condition that required surgical intervention exclusion criteria: 1. scar localization on acral or hair bearing sites 2. patients unable to converse in english 3. patients requiring flap or graft for closure of wound 4. history of allergy to adhesives 5. patient using topical chemotherapy agents on the surgical site or planning to start it within 3 months after surgery 6. use of hydrocolloid dressings for post-operative wound care in the past

Keywords: scar dermatologic surgery wound healing wound of skin skin cancer surgical incision patient satisfaction patient preference cosmetic outcome scar appearance
work organization and cardiovascular disease

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: to determine the combined effects of job strain and social isolation on cardiovascular morbidity and mortality.

background: much of the medical and epidemiological research on the causes of cardiovascular disease has concentrated either on individual life style behaviors such as smoking and exercise or on biomedical risk factors such as hypertension, and diabetes. this research has provided the basis for improvements in personal health behaviors and in the treatment of hypertension which has reduced the incidence of cardiovascular disease in this country. however, even the best statistical models, incorporating all such risk factors, leave a significant proportion of cardiovascular disease mortality and morbidity unexplained. major differences in cardiovascular disease rates have also been observed between different social classes and different societies. these findings have led epidemiologists and sociomedical researchers to investigate other types of variables, including psychosocial factors, such as personal predispositions, social support networks, and work-related stress. a series of studies, in a variety of disciplines, suggested that occupational stress may contribute to the development of cardiovascular disease. a major source of data was the swedish survey of living conditions (ulf). the ulf was drawn from a sample which included the total occupational and demographic variation of an entire society. the survey contained information on age, sex, marital status, occupational class background and nationality of respondents and parents, residence, education, past employment history and income data. design narrative: in this non-concurrent prospective study, ten years of follow-up data were linked with five years of data from the survey of living conditions collected between 1976 and 1980. total and cause-specific mortality data were obtained from the swedish national death registry and morbidity incidence data from the registry of hospitalizations. the relationship between the duration of exposure time and disease risk was examined utilizing occupational history information which was combined with theorell's occupational psychosocial scoring system. logistic regression analysis was used to examine the relative risks associated with adverse work characteristics and to test for potential interactions and confounding effects. cox's proportional hazards model was used as an approximation of life table methods. analysis was performed separately for men and women. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
cd7 car t-cell for r/r cd7+ t cell lymphoma

Conditions: Refractory and Relapsed T Cell Lymphoma

Summary: this is a prospective, open-label, multiple center and single arm phase 2 study to evaluate the efficacy and safety of t cells expressing humanized cd7 chimeric antigen receptors treatment for patients with refractory/relapsed cd7 positive t cell lymphoma.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. r/r t-nhl with measurable (≧1.5cm) lesions confirmed by pathological immunohistochemistry or flow cytometry 3. the expressions of both cd4 and cd8 are negative in patients with bone marrow involved 4. the eastern cooperative oncoloy group (ecog) physical condition score ≤ 2 points 5. the main organ functions need to meet the following conditions: a.left ventricular ejection fraction ≥50% b.creatinine ≤132umol/l or creatinine clearance ≥60 ml/min c.alt and ast≤2.5 upper limitation of normal d.t-bil≤2.0mg/dl e.spo2 \> 90% 6. results of pregnant test should be negative, and agree to conception control during treatment and 1 year after car-t infusion 7. expected survival exceeds 3 months 8. written informed consent could be acquired exclusion criteria: 1. immunosuppressant medications or steroids were used within 2 weeks before cell collection, or need to use steroids or immunosuppressant medications more than two years 2. patients with uncontrolled active infection 3. active hepatitis b or hepatitis c infection 4. patients with hiv infection 5. severe acute or chronic graft-versus-host disease (gvhd) 6. participated in any other drug research clinical trials within 30 days before enrollment 7. prior car-t cells therapy within 3 months before enrollment 8. prior allogeneic hematopoietic stem cell transplantation within 6 months before enrollment 9. uncontrolled other tumor 10. women in pregnancy, lactation or planning to become pregnant 11. the researcher considers inappropriate to participate in this research
acid production in dental plaque after exposure to probiotic bacteria

Conditions: Caries

Summary: the increasing interest in probiotic lactobacilli in health maintenance has raised the question of potential risks. one possible side effect could be an increased acidogenicity in dental plaque. the aim of this study was to investigate the effect of probiotic lactobacilli on plaque lactic acid (la) production in vitro and in vivo. methods. subjects (n=18) were given lozenges with probiotic lactobacilli (l. reuteri dsm 17938 and atcc pta 5289) or placebo for two weeks in a double-blinded, randomized cross-over trial. the concentration of la in supragingival plaque samples was determined at baseline and after 2 weeks. salivary counts of mutans streptococci (ms) and lactobacilli were estimated with chair-side methods.


Eligibility criteria:
inclusion criteria: * moderate to high counts of salivary mutans streptococci (\>104 cfu) as estimated with the dentocult sm chair-side test, * no visible open caries lesions or periodontal disease, exclusion criteria: * smokers, * ingestion of probiotic bacteria within the last two months, * ingestion of antibiotics within the last two months

Keywords: caries, probiotic bacteria
factor xi levels in acute ischemic stroke

Conditions: Stroke

Summary: the purpose of this study is to evaluate the utility of measuring coagulation factor activities in the setting of acute ischemic stroke, as potential markers of inherited thrombotic risk. the investigators will determine if relationships exist between coagulation factors, including factor viii, factor ix, and factor xi and clinical diagnosis, classification, and outcome. the investigators will determine if any significant elevations of these factor activities are independent thrombotic risk factors. null hypothesis: there is no statistical difference between coagulation factors, including factors viii, ix, or xi activity levels in patients having acute ischemic stroke as compared to acute stroke mimics.

increased factor xi levels have been associated with venous thromboembolic disease and acute myocardial infarction. however, checking factor xi levels is not currently indicated to assess individual thromboembolic risk. factor xi is an important protease that links the extrinsic arm of the coagulation cascade with the intrinsic arm through dual activation by both factor xii and thrombin. since thrombin is a downstream product of factor xi, a feedback loop is created that amplifies thrombin production and ultimately results formation of a stable fibrin clot. sufficient thrombin generation via this pathway also contributes to activation of the thrombin-activatable fibrinolysis inhibitor (tafi). activated tafi downregulates fibrinolysis and has been implicated as part of the association between elevated factor xi levels and venous thromboembolic disease. one study found that functional tafi levels of \> 120% increased the risk of ischemic stroke approximately 6-fold, however, the association between factor xi and ischemic stroke has yet to be firmly established. we recently performed a preliminary retrospective analysis of 78 patients with stroke or transient ischemic attack (tia) and found that patients with factor xi activity levels above the 95th percentile of an age and sex matched reference population had a relative risk of 5.3 for stroke or tia. factor xi measurements may be able to help identify thromboembolic disease, aiding in the determination of stroke etiology.

Eligibility criteria:
inclusion criteria: * those clinically diagnosed with acute ischemic stroke * 18 years of age or greater exclusion criteria: * those without clinical diagnosis of acute ischemic stroke will be included in the control group. * patients with hemorrhagic strokes * inpatients who are evaluated through the brain attack protocol

Keywords: acute ischemic stroke
association of oral helicobacter pylori infection with gastric helicobacter pylori infection

Conditions: Helicobacter Pylori

Summary: the aim of this study was to investigate the association between oral helicobacter pylori infection and gastric helicobacter pylori infection. patients who were tested for gastric helicobacter pylori were tested for oral helicobacter pylori at the same time, and were divided into four groups according to the test results to compare the positive rate of oral helicobacter pylori.


Eligibility criteria:
inclusion criteria: 1. age between 18\~70 ,both gender. 2. initial diagnosis of stomach helicobacter pylori infection or never had helicobacter pylori infection. 3. have not received dental care or systemic periodontal basic treatment in the past 1 year. exclusion criteria: 1. there is serious organ damage and complications (such as cirrhosis, uremia, etc.), severe or unstable cardiopulmonary or endocrine diseases. 2. ongoing use of antiulcer medications (including ppis taken within 2 weeks before helicobacter pylori infection testing), antibiotics, or bismuth complexes (more than 3 times/week before screening). 3. those with severe oral diseases and malignant tumors of the mouth. 4. previously had upper gastrointestinal surgery. 5. refusal to sign informed consent.

Keywords: oral helicobacter pylori helicobacter pylori gastric
long term follow-up registry of individuals treated in a gilead-sponsored trial in individuals with chronic hepatitis b infection

Conditions: Chronic Hepatitis B

Summary: this study will evaluate the long term effects of hepatitis b virus (hbv) treatment on the hbv serologic changes and hbv dna levels through week 144. this registry will enroll only individuals who were treated in a gilead-sponsored trial for chronic hepatitis b (chb).


Eligibility criteria:
key inclusion criteria: * must have participated in a gilead-sponsored chronic hepatitis b (chb) study no more than 120 days prior to baseline (day 1), except for participants from previous gilead-sponsored study number gs-us-174-0149, who will have up to one year from their last visit in that protocol. * must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures * must be willing and able to comply with the visit schedule and study requirements * must have documented hbv dna \< 2,000 iu/ml at time of screening visit, which shall occur no later than 1 year post last study visit in gs-us-174-0149 * must have documented hepatitis b surface antigen (hbsag) negative status anytime during participation in gs-us-174-0149 regardless of ongoing hbv treatment key exclusion criteria: * patient participating or planning to participate in another clinical study with an investigational agent * history of clinically-significant illness or any other major medical disorder that may interfere with follow-up, assessments or compliance with the protocol * believed by the study investigator to be inappropriate for study participation for any reason not otherwise listed * received tdf monotherapy either as part of gs-us-174-0149 arm c (tdf monotherapy arm) or for tdf retreatment, and have taken any hbv antiviral therapy since completion of gs-us-174-0149 note: other protocol defined inclusion/exclusion criteria may apply.
comparison between ofdi and ivus in pci guidance for biolimus a9 eluting stent implantation

Conditions: Coronary Artery Disease

Summary: the aim of this study is to assess clinical safety and efficacy of percutaneous coronary intervention (pci) using a newer generation drug-eluting stent (des) in the context of optical frequency domain imaging (ofdi) guidance or intravascular ultrasound (ivus) guidance.

intracoronary imaging techniques provide clinically useful information in the setting of pci, such as lesion severity, tissue characterization, vessel sizing, and stent optimization. current evidences suggest potential advantage of intracoronary imaging guidance in reducing the risk of major adverse cardiac events after stent implantation over conventional pci under angiographic guidance alone. ivus has been clinically used in two decades and it is known as one of the most dominant intracoronary imaging technique. ofdi is a new light-based intracoronary imaging technology which provides higher image resolution and higher-speed pullback compared to those of ivus. given the different properties between ultrasound-based ivus and light-based ofdi, treatment and clinical impact of these two imaging techniques would be different.

Eligibility criteria:
inclusion criteria: * patients with stable coronary artery disease who have symptoms or myocardial ischemia proven by non-invasive or invasive stress test. exclusion criteria: * renal insufficiency with estimated glomerular filtration rate (egfr) \<45 ml/min/1.73m2 * left ventricular ejection fraction (lvef) \<30% or history of congestive heart failure * acute coronary syndrome within 7 days after onset * considered as inappropriate for drug-eluting stent (des) use or dual antiplatelet therapy for one year after the index procedure * life expectancy within one year * lesion length estimated by quantitative coronary angiography (qca) \>28mm * chronic total occlusion * left main stem lesion * bifurcation requiring side branch balloon dilatation * severely calcified lesion * other conditions by which physicians in charge judged inappropriate to enroll the patients because of safety concern.

Keywords: intracoronary imaging optical frequency domain imaging intravascular ultrasound percutaneous coronary intervention drug eluting stent
inhibiting dietary iron absorption in subjects with hereditary hemochromatosis by a natural polyphenol supplement

Conditions: Iron Metabolism Disorders; Iron Overload; Polyphenols

Summary: polyphenolic compounds are very strong inhibitors of non-heme iron absorption, as they form insoluble complexes with ferrous iron. patients with hereditary hemochromatosis (hh) have an increased intestinal non-heme iron absorption due to a genetic mutation in the regulatory pathway, leading to excess iron in the body. this study investigates the inhibitory effect of a natural polyphenol supplement in participants with hh.


Eligibility criteria:
inclusion criteria: * homozygous for c282y mutation in hfe (hemochromatosis) gene * written informed consent * age 18-65 y * not pregnant or lactating * body weight \< 75 kg * body mass index (bmi) between 18.5 and 25 kg/m2 * no acute illness/infection (self-reported) * no metabolic or gastrointestinal disorders, eating disorders or food allergy to the ingredients of the test meal (self-reported) * no scheduled phlebotomy throughout the study period * the last phlebotomy will be at least 4 weeks prior first test meal administration * no use of medications affecting iron absorption or metabolism during the study * no intake of mineral/vitamin supplements 2 weeks before the first study day and during the study * participation in any other clinical study within the last 30 days * expected to comply with study protocol
excimer laser phototherapy outcomes in the treatment of psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to determine the best dosing strategy when using excimer laser to treat plaque-type psoriasis. in this study, half of the body's psoriasis will be treated with a new dosing strategy, and the other half will be treated with the conventional method. we hope to show that the new dosing strategy will result in faster improvement of psoriasis.

this is a randomized, assessor-blinded clinical trial to determine whether a novel plaque-based dosimetry strategy can improve the speed of response to excimer laser treatment in patients with plaque psoriasis. each patient will receive plaque-based dosing on one side of the body and conventional dosing on the contralateral side. this design is based on the assumption that psoriasis usually affects patients in a symmetric distribution (e.g., knees and elbows) and the effect of excimer laser phototherapy is limited to the treated plaque. the side of the body treated with plaque-based dosimetry will be assigned using a table of random numbers. the assessor will be blinded to the treatment group. each patient will be treated 1-2 times per week at the discretion of the investigator for a maximum of 10 treatments.

Eligibility criteria:
inclusion criteria: 1. diagnosis of chronic plaque psoriasis for at least 6 months 2. age ≥ 18 years 3. body surface area affected ≤ 10 percent 4. presence of at least one pair of bilateral target lesions with an area of at least 20 cm2 per target lesion. the bilateral target lesions must be present in the same category of anatomical region (e.g., bilateral lower extremities, bilateral upper extremities or bilateral trunk). exclusion criteria: 1. active or past history of erythrodermic psoriasis, guttate psoriasis, or pustular psoriasis 2. history of photosensitivity disorder 3. history of malignant melanoma 4. active, invasive non-melanoma skin carcinoma 5. fitzpatrick skin type i 6. subject has received ultraviolet b phototherapy or any topical anti-psoriatic therapy within two weeks prior to starting the study. 7. subject has received systemic or topical psoralen-ultraviolet a photochemotherapy within four weeks prior to starting the study. 8. subject has received biologic therapy within three months of starting the study.